脾多肽对非小细胞肺癌患者化疗后骨髓造血功能的影响

Effect of splenic polypeptide on hematopoietic function in patients with non-small cell lung cancer after chemotherapy

摘要:

目的 观察脾多肽对非小细胞肺癌患者化疗后造血功能的影响及其最佳剂量。方法 回顾性分析152例进行化疗的非小细胞肺癌患者，按有无使用脾多肽，分为对照组和治疗组。对照组给予常规化疗，治疗组在常规化疗基础上联合使用脾多肽注射液≥ 7 d。观察两组患者血细胞下降的最低值，重组人粒细胞集落刺激因子（G-CSF）药物使用量及不良反应。结果 两组化疗后白细胞、血小板最低值比较，差异无统计学意义（P >0.05）；两组化疗后中性粒细胞最低值比较，差异有统计学意义（P <0.05）。以不同脾多肽注射液剂量分为2 ml、4 ml、6 ml、10 ml组，脾多肽注射液10 ml组白细胞、中性粒细胞最低值高于其他剂量组及对照组（P <0.05）；各组血小板最低值比较，差异无统计学意义（P >0.05）。脾多肽注射液10 ml组G-CSF的使用时间较对照组减少（P <0.05）。各组患者不良反应发生率比较，差异无统计学意义（P >0.05），主要为恶心呕吐及神经毒性。结论 大剂量脾多肽对非小细胞肺癌患者化疗后骨髓造血功能有保护作用，其最佳剂量可能为10 ml。

Abstract:

Objective To observe the effect of splenic polypeptide on hematopoietic function in patients with non-small cell lung cancer after chemotherapy.Methods A retrospective analysis was made on 152 patients with non-small cell lung cancer who received chemotherapy. They were divided into control group and treatment group according to whether or not spleen polypeptide was used. The control group was given routine chemotherapy. The treatment group was combined with spleen polypeptide injection on the basis of routine chemotherapy for at least 7 days. The lowest blood cell decline, the use of G-CSF, and adverse reactions were observed in the two groups.Results The lowest values of leukocyte and platelet in treatment group and control group were no significant difference (P > 0.05)；the lowest values of neutrophil were respectively, with significant difference (P < 0.05). According different doses of splenic polypeptide were divided into control group, 2 ml, 4 ml, 6 ml, and 10 ml subgroups. The lowest values of white blood cells and neutrophils in 10 ml splenic polypeptide group were significantly higher than those in other dose groups (P < 0.05), while the lowest values of platelets in different splenic polypeptide dose groups had no significant difference (P > 0.05). The days of using G-CSF in 10 ml splenic polypeptide group was significantly lower than that in control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). The mainly adverse reactions were nausea, vomiting, and neurotoxicity.Conclusion High-dose splenic polypeptide has protective effect on bone marrow hematopoietic function in patients with non-small cell lung cancer after chemotherapy, and the befitting dose maybe is 10 ml.